Pharmaron Acquires Recipharm’s Commercial API Manufacturing Facility in the United Kingdom

Pharmaron Acquires Recipharm’s Commercial API
On January 9, Pharmaron Beijing Co., Limited announced the acquisition of Aesica Pharmaceuticals Limited from Recipharm.

The Cramlington Site in Newcastle, United Kingdom, has a long history of providing cGMP manufacturing services for various Active Pharmaceutical Ingredients (API), from pilot to commercial metric ton scale. The Cramlington Site has a commercial reactor capacity of more than 100 cubic meters and has been examined and certified by the MHRA, the FDA, and other regulatory bodies.

This purchase strengthens Pharmaron's global chemical and manufacturing capabilities, which are a critical component of the company's fully integrated platform. The synergistic integration of the Cramlington Site with Pharmaron's current service capabilities in discovery, process development, and early-stage cGMP API manufacture in Hoddesdon will enable the United Kingdom to have a comprehensive end-to-end chemical and manufacturing offering. Furthermore, this addition extends Pharmaron's global service network, allowing us to deliver bespoke solutions tailored to our clients' geographic and strategic requirements.

 "We are delighted to have the Cramlington Site join the Pharmaron Group. This acquisition complements and further enhances Pharmaron’s CMC capabilities in the United Kingdom and China. We are committed to expanding the Cramlington site to meet growing demand. Together with our API manufacturing facility expansion in China, this transaction is another important step in realizing our vision of becoming a leading global provider of integrated small-molecule drug R&D and manufacturing services."

-Dr. Boliang Lou, Chairman and Chief Executive Officer of Pharmaron

Marc Funk, CEO of Recipharm, commented, This divestment helps us to streamline our operations in line with our strategic goals and better align with our customers’ evolving needs. In addition, I am pleased that the Cramlington Site will get a committed owner with the capacity and capability to develop it to its full potential. As a top five global CDMO, we will continue to develop and invest in our highly successful contract manufacturing business.

Goetzpartners Securities served as Pharmaron's exclusive financial advisor, while O'Melveny served as legal counsel. Results Healthcare served as Recipharm's exclusive financial advisor, while Addleshaw Goddard served as its legal counsel.